SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
1-Year Return
18.59%
This Quarter Return
+20.08%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.37B
AUM Growth
+$183M
(+8.4%)
Cap. Flow
-$178M
Cap. Flow
% of AUM
-7.51%
Top 10 Holdings %
Top 10 Hldgs %
42.39%
Holding
113
New
23
Increased
16
Reduced
30
Closed
11
Top Buys
| 1 |
Coca-Cola
KO
|
$33.4M |
| 2 |
Apple
AAPL
|
$30.3M |
| 3 |
CRH
CRH
|
$28.9M |
| 4 |
ArriVent BioPharma
AVBP
|
$27.9M |
| 5 |
argenx
ARGX
|
$26.9M |
Top Sells
| 1 |
Arcellx
ACLX
|
$60.8M |
| 2 |
Royalty Pharma
RPRX
|
$49.7M |
| 3 |
Las Vegas Sands
LVS
|
$36.3M |
| 4 |
Microsoft
MSFT
|
$34.8M |
| 5 |
Biohaven
BHVN
|
$31.2M |
Sector Composition
| 1 | Healthcare | 65.84% |
| 2 | Technology | 8.92% |
| 3 | Communication Services | 8% |
| 4 | Consumer Discretionary | 5.07% |
| 5 | Financials | 3.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
InflaRx
IFRX
$112M
| $8.83M | 0.33% |
5,733,910
| – | – |
|
52
Elanco Animal Health
ELAN
$9.16B
| $8.26M | 0.31% |
507,200
-107,100
| -17% | -$1.74M |
|
|
RVNC
53
DELISTED
Revance Therapeutics, Inc.
RVNC
| $7.87M | 0.29% |
+1,600,000
| New | +$7.87M |
|
54
UnitedHealth
UNH
$286B
| $7.48M | 0.28% |
15,123
+2,300
| +18% | +$1.14M |
|
55
Zura Bio
ZURA
$143M
| $7.32M | 0.27% |
2,850,000
| – | – |
|
56
GE HealthCare
GEHC
$34.6B
| $6.82M | 0.25% |
+75,000
| New | +$6.82M |
|
57
Korro Bio
KRRO
$312M
| $6.64M | 0.25% |
73,821
| – | – |
|
58
Kezar Life Sciences
KZR
$29.8M
| $6.46M | 0.24% |
716,759
| – | – |
|
59
ProKidney
PROK
$304M
| $6.34M | 0.24% |
3,867,847
| – | – |
|
60
Spyre Therapeutics
SYRE
$1.03B
| $6.16M | 0.23% |
162,395
| – | – |
|
61
Alnylam Pharmaceuticals
ALNY
$59.2B
| $4.88M | 0.18% |
32,660
+22,800
| +231% | +$3.41M |
|
62
Thermo Fisher Scientific
TMO
$186B
| $4.22M | 0.16% |
7,260
| – | – |
|
63
Danaher
DHR
$143B
| $4.1M | 0.15% |
16,427
| – | – |
|
64
Abbott
ABT
$231B
| $3.81M | 0.14% |
33,520
| – | – |
|
65
Teva Pharmaceuticals
TEVA
$21.7B
| $3.78M | 0.14% |
268,100
-229,300
| -46% | -$3.24M |
|
66
Gilead Sciences
GILD
$143B
| $3.71M | 0.14% |
50,700
+28,000
| +123% | +$2.05M |
|
67
Kenvue
KVUE
$35.7B
| $3.68M | 0.14% |
171,596
| – | – |
|
68
Cencora
COR
$56.7B
| $3.03M | 0.11% |
12,488
| – | – |
|
69
Tourmaline Bio
TRML
$687M
| $2.86M | 0.11% |
+125,000
| New | +$2.86M |
|
70
Mettler-Toledo International
MTD
$26.9B
| $2.61M | 0.1% |
+1,964
| New | +$2.61M |
|
71
Natera
NTRA
$23.1B
| $2.25M | 0.08% |
24,600
| – | – |
|
72
Cogent Biosciences
COGT
$1.82B
| $2.12M | 0.08% |
316,000
-3,394,539
| -91% | -$22.8M |
|
73
Intuitive Surgical
ISRG
$167B
| $2.08M | 0.08% |
5,200
+2,130
| +69% | +$850K |
|
74
Avantor
AVTR
$9.07B
| $1.84M | 0.07% |
71,850
+33,600
| +88% | +$859K |
|
75
IQVIA
IQV
$31.9B
| $1.81M | 0.07% |
7,175
| – | – |
|